Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IDXX logo IDXX
Upturn stock ratingUpturn stock rating
IDXX logo

IDEXX Laboratories Inc (IDXX)

Upturn stock ratingUpturn stock rating
$636.91
Last Close (24-hour delay)
Profit since last BUY30.89%
upturn advisory
WEAK BUY
BUY since 111 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/14/2025: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $697.17

1 Year Target Price $697.17

Analysts Price Target For last 52 week
$697.17 Target price
52w Low $356.14
Current$636.91
52w High $688.12

Analysis of Past Performance

Type Stock
Historic Profit 16.79%
Avg. Invested days 37
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 50.67B USD
Price to earnings Ratio 52.65
1Y Target Price 697.17
Price to earnings Ratio 52.65
1Y Target Price 697.17
Volume (30-day avg) 13
Beta 1.58
52 Weeks Range 356.14 - 688.12
Updated Date 10/13/2025
52 Weeks Range 356.14 - 688.12
Updated Date 10/13/2025
Dividends yield (FY) -
Basic EPS (TTM) 12.03

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 24.41%
Operating Margin (TTM) 33.62%

Management Effectiveness

Return on Assets (TTM) 23.26%
Return on Equity (TTM) 64.87%

Valuation

Trailing PE 52.65
Forward PE 44.64
Enterprise Value 51782852244
Price to Sales(TTM) 12.55
Enterprise Value 51782852244
Price to Sales(TTM) 12.55
Enterprise Value to Revenue 12.82
Enterprise Value to EBITDA 37
Shares Outstanding 80004694
Shares Floating 79117442
Shares Outstanding 80004694
Shares Floating 79117442
Percent Insiders 0.68
Percent Institutions 97.4

ai summary icon Upturn AI SWOT

IDEXX Laboratories Inc

stock logo

Company Overview

overview logo History and Background

IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine. It began with developing and marketing diagnostic tests for animal health and has grown into a global leader in pet healthcare innovation, providing diagnostics and software to veterinary practices worldwide.

business area logo Core Business Areas

  • CAG Diagnostics: Offers diagnostic products and services for companion animals, including in-clinic diagnostic instruments, reference laboratory services, and rapid assay tests. This is their largest segment.
  • Water: Develops and manufactures products used to test water for microbiological and chemical contaminants.
  • Livestock, Poultry and Dairy (LPD): Provides diagnostic tests for livestock, poultry, and dairy animals to help manage animal health and food safety.

leadership logo Leadership and Structure

IDEXX Laboratories is led by Jay Mazelsky (President and CEO). The organizational structure is departmentalized, with divisions focusing on each of the core business areas.

Top Products and Market Share

overview logo Key Offerings

  • Catalyst Dx Chemistry Analyzer: In-clinic chemistry analyzer used to run blood tests. IDEXX holds a significant market share in this area, estimated above 50%. Competitors: Zoetis, Heska (now part of Mars).
  • VetConnect PLUS: Software platform integrating diagnostics data and practice management. Competitors include cloud-based practice management software.
  • SNAP Tests: Rapid immunoassay tests for various animal diseases. Estimated above 40% of market share. Competitors: Zoetis, Heska (now part of Mars).

Market Dynamics

industry overview logo Industry Overview

The animal health diagnostics industry is growing, driven by increasing pet ownership, higher spending on pet healthcare, and technological advancements in diagnostics.

Positioning

IDEXX is a leading player, known for its innovative diagnostic solutions and its integrated service offerings, creating a robust competitive edge.

Total Addressable Market (TAM)

The global animal health market is expected to exceed $75 billion by 2030. IDEXX is well positioned to capture a significant portion of this market due to its strong presence in diagnostics.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition
  • Extensive product portfolio
  • Global presence
  • Innovative technology
  • High customer loyalty

Weaknesses

  • High dependence on companion animal diagnostics
  • Premium pricing may limit affordability for some customers
  • Geographic concentration of manufacturing

Opportunities

  • Expanding into emerging markets
  • Developing new diagnostic tests for livestock
  • Further integrating diagnostics with telemedicine
  • Partnerships and acquisitions to expand product offerings

Threats

  • Intense competition
  • Economic downturn affecting pet spending
  • Regulatory changes in diagnostic testing
  • Disruptive technologies from new entrants
  • Supply chain disruptions

Competitors and Market Share

competitor logo Key Competitors

  • ZTS
  • VET
  • ELAN

Competitive Landscape

IDEXX's competitive advantages include its integrated diagnostic solutions, strong brand reputation, and global presence. Disadvantages include premium pricing compared to some competitors.

Major Acquisitions

ezyVet

  • Year: 2021
  • Acquisition Price (USD millions): 210
  • Strategic Rationale: The acquisition of ezyVet, a cloud-based practice management software, strengthens IDEXX's software offerings and integrates diagnostics data with practice workflows.

Growth Trajectory and Initiatives

Historical Growth: IDEXX has demonstrated consistent revenue and earnings growth over the past decade, driven by increasing pet ownership and veterinary spending.

Future Projections: Analysts project continued revenue growth in the high single digits, driven by new product launches and expansion into emerging markets.

Recent Initiatives: Recent initiatives include expanding reference laboratory services, launching new diagnostic tests, and investing in digital technologies.

Summary

IDEXX is a strong company with a leading position in the animal health diagnostics market. Its growth is driven by innovation and increasing pet healthcare spending. Key strengths include its brand and integrated solutions, while potential threats involve competition and economic conditions. The company should be prepared for economic downturn and further expand to global markets.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is based on available information and is for informational purposes only. It should not be considered financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About IDEXX Laboratories Inc

Exchange NASDAQ
Headquaters Westbrook, ME, United States
IPO Launch date 1991-06-21
President, CEO & Director Mr. Jonathan J. Mazelsky
Sector Healthcare
Industry Diagnostics & Research
Full time employees 11000
Full time employees 11000

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.